sci-news.jpeg

sci-news

shimin.jpeg

shimin

eppharmaline.gif

eppharmaline

findat.jpeg

findat

yakuzemi.png

yakuzemi

new-lifescience.gif

new-lifescience

biopharmaceuticals.gif

biopharmaceuticals

jssx36.png

jssx36

convention.jpeg

convention

jshp2022-thk.png

jshp2022-thk

jasdi24.png

jasdi24

General information

Announcements(0)

Greetings from Chair

Overview

Registration

General information 2

Abstract Submission (Oral/Poster Presentation)

Program

Sessions

Search presentations

pharm142_en.png

Change account information such as the email address and password on the account setting screen common to Confit.

Login required to view

Password required to view

Presentation Information

Session Details

A password that applicants have been notified of is required to view abstracts.<br>If you are a participant and need to confirm the password, please contact us by e-mail about which annual meeting you would like to know the password for to view abstracts.<br>We will reply after confirming that you were a participant.<br>Thank you for your understanding.

To browse or post comments, you must log in.

You cannot post comments as it is outside the comment posting period.

This comment has been deleted. You cannot reply to this comment.

Program Type

Announcements

Profile management

Bookmark

Download PDF for print

Timetable

OASIS in myofibroblasts contributes to the development of kidney fibrosis

Fibrosis occurs in major organs, such as the heart, kidney, liver, and pancreas. The fibrotic organs eventually become dysfunctional. Fibrosis is also observed in cancer development and involved in the formation of tumor microenvironment. Fibrosis has so far been considered as an irreversible condition, having focused on the prevention rather than the treatment. However, several recent reports have shown that fibrotic state is reversible and proposed new therapeutic strategies for fibrosis treatment. Fibrosis is caused by excessive accumulation of extracellular matrix (ECM). Although ECM-secreting cells are different in different organs where fibrosis is organ-specifically induced, some mechanisms for fibrosis are likely common in these organs. Thus, understanding fibrosis in a cross-organ manner may be great benefit for the development of new therapeutic approaches. In this symposium, we present and discuss the latest results of our fibrosis research targeting ECM-producing cells in various organs, which allow us to deepen our understanding of fibrosis mechanism and to develop new approaches for fibrosis therapy.<br />

Advanced approaches to fibrosis treatment by considering various organs

The 142nd Annual Meeting of the Pharmaceutical Society of Japan (Nagoya)

Presentation Information

[GS02-1]OASIS in myofibroblasts contributes to the development of kidney fibrosis

Password required to view